Payment overview · 2025
General Payments
$115.94
7 reported records · 3 companies
Healthcare provider profile · identity verified
Glenna S Jackson, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MEDINA, OH · NPI 1003887779
Verified facts
What the public records show
CMS Open Payments records show Glenna S Jackson, M.D. received $115.94 in general payments during 2025 across 7 reported records.
ABBVIE INC. accounted for 44.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Nurtec Odt.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $51.91 | 44.8% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $50.18 | 43.3% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.85 | 11.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $115.94 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $50.18 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $34.56 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $30.29 | 2 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $21.62 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.62 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.85 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 123 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
155 | 40 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
123 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 955 | 269 |
| Levothyroxine Sodium | Levothyroxine Sodium | 695 | 167 |
| Lisinopril | Lisinopril | 559 | 168 |
| Amlodipine Besylate | Amlodipine Besylate | 454 | 127 |
| Losartan Potassium | Losartan Potassium | 435 | 108 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 383 | 106 |
| Simvastatin | Simvastatin | 347 | 98 |
| Metoprolol Succinate | Metoprolol Succinate | 331 | 86 |
| Hydrochlorothiazide | Hydrochlorothiazide | 319 | 85 |
| Metformin Hcl | Metformin Hcl | 269 | 70 |
| Pantoprazole Sodium | Pantoprazole Sodium | 263 | 84 |
| Omeprazole | Omeprazole | 235 | 62 |
| Alendronate Sodium | Alendronate Sodium | 198 | 42 |
| Glimepiride | Glimepiride | 186 | 48 |
| Pioglitazone Hcl | Pioglitazone Hcl | 184 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 176 | 55 |
| Gabapentin | Gabapentin | 171 | 41 |
| Synthroid | Levothyroxine Sodium | 155 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 135 | 38 |
| Buspirone Hcl | Buspirone Hcl | 130 | 35 |
| Montelukast Sodium | Montelukast Sodium | 126 | 43 |
| Eliquis | Apixaban | 123 | 32 |
| Sertraline Hcl | Sertraline Hcl | 118 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 117 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 117 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 116 | 56 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 112 | 28 |
| Trazodone Hcl | Trazodone Hcl | 108 | 32 |
| Valsartan | Valsartan | 101 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 100 | 30 |
| Bupropion Hcl | Bupropion Hcl | 99 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 99 | 23 |
| Atenolol | Atenolol | 98 | 23 |
| Meloxicam | Meloxicam | 96 | 25 |
| Metformin Hcl Er | Metformin Hcl | 95 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 94 | 32 |
| Furosemide | Furosemide | 91 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 91 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 90 | 46 |
| Fluoxetine Hcl | Fluoxetine Hcl | 83 | 20 |
| Allopurinol | Allopurinol | 79 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 75 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 72 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 71 | 21 |
| Carvedilol | Carvedilol | 69 | 18 |
| Baclofen | Baclofen | 64 | 13 |
| Potassium Chloride | Potassium Chloride | 64 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 63 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 61 | 17 |
| Ezetimibe | Ezetimibe | 60 | 15 |
| Bupropion Xl | Bupropion Hcl | 58 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 53 | 13 |
| Celecoxib | Celecoxib | 50 | 13 |
| Prednisone | Prednisone | 50 | 39 |
| Jardiance | Empagliflozin | 46 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 45 | 43 |
| Famotidine | Famotidine | 45 | suppressed |
| Spironolactone | Spironolactone | 41 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | 12 |
| Lorazepam | Lorazepam | 40 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 40 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 39 | 15 |
| Colesevelam Hcl | Colesevelam Hcl | 38 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 38 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 38 | 12 |
| Farxiga | Dapagliflozin Propanediol | 37 | suppressed |
| Fenofibrate | Fenofibrate | 36 | 11 |
| Trulicity | Dulaglutide | 36 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 33 |
| Terazosin Hcl | Terazosin Hcl | 35 | suppressed |
| Lovastatin | Lovastatin | 34 | 11 |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 33 | 22 |
| Finasteride | Finasteride | 33 | suppressed |
| Lamotrigine | Lamotrigine | 33 | suppressed |
| Mirtazapine | Mirtazapine | 33 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 33 | suppressed |
| Sucralfate | Sucralfate | 32 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 30 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 30 |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Estradiol | Estradiol | 27 | 12 |
| Gemfibrozil | Gemfibrozil | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | 16 |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 12 |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Ozempic | Semaglutide | 21 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 16 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Alprazolam | Alprazolam | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Nabumetone | Nabumetone | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Novolin R | Insulin Regular, Human | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | 11 |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Dexmethylphenidate Hcl Er | Dexmethylphenidate Hcl | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Oxaprozin | Oxaprozin | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $115.94 · 7 records | ABBVIE INC. | AREXVY, ELIQUIS, MAVYRET, NURTEC ODT, SHINGRIX, VRAYLAR, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error